Abstract:Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. It has been considered as one of the drug targets of diabetes, and the inhibitors for PTP1B to treat type II diabetes have received considerable attention. The study reports a discovery of a new lead compound inhibiting PTP1B. In this work, PTP1B protein was expressed, purified and crystallized to the resolution of 2.1 Angstrom in the condition of 19%similar to 21% PEG8000, 200 mmol/L Mg(Ac)(2)center dot 4H(2)O. Structural based fragment screening was then performed against 768 fragment chemical compounds. These small molecular fragments were soaked with the PTP1B crystals, and three of them were found to bind at the active site A of PTP1B in the crystals. Then 14 kinds of published molecules which bind to the second active site (site B) were chosen. With the structures of these bound fragment compounds, hundreds of moleculars were calculated by computer aided drug design. Compound 20 was selected as the target compound, and it was synthesized by 13 steps with the total yield of 1.7%. The structure of compound 20 was characterized by H-1 NMR and HRMS data. Bioassay of inhibition of PTP1B by the new compounds revealed its IC50 at (3.4 +/- 1.2) mu mol/L, which was better than that of the positive control drug-sodium vanadate. The result of measurement of glucose uptake by insulin resistant HepG2 cells showed that the new compound can improve glucose uptake and had similar effect as Pioglitazone. The acute toxicity of the new compound was tested by using zebrafish larvae at two different concentrations (50 and 500 mu mol/L). The results showed there was no significant difference in heart rate, blood flow and morphology between the experiment and control group of zebrafish. All the results above implied the new compound has a good inhibition on PTP1B and low acute toxicity. It may be a potential lead compound for further drug discovery.

Identification of 1,3,4-Thiadiazolyl-Containing Thiazolidine-2,4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Synthesis, Biological Evaluation and 3D-QSAR Studies of Imidazolidine-2,4-dione Derivatives As Novel Protein Tyrosine Phosphatase 1B Inhibitors

Synthesis and Ptp1b Inhibitory Activity of (E)-1-substitutedphenyl-3-(4-((e)-(2-(4-phenylthiazol-2-yl)hydrazono)met Hyl)Pheny1)-Prop-2-En-1-Ones

Design and synthesis of imidazolidine-2,4-dione derivatives as selective inhibitors by targeting protein tyrosine phosphatase-1B over T-cell protein tyrosine phosphatase.

Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties

Discovery of Bisindole As A Novel Scaffold for Protein Tyrosine Phosphatase 1b Inhibitors

Synthesis and Protein Tyrosine Phosphatase 1b Inhibitory Activity of Novel Chalcone Derivatives Containing 3,4-Dihydroquinolin-2(1h)-one Moiety

Discovery of 2-Ethoxy-4-(methoxymethyl)benzamide Derivatives As Potent and Selective PTP1B Inhibitors.

Thiazole-based and Thiazolidine-Based Protein Tyrosine Phosphatase 1B Inhibitors As Potential Anti-Diabetes Agents

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

Synthesis and Biological Evaluation of Novel Bis-Aromatic Amides As Novel PTP1B Inhibitors

Design and Biological Evaluation of Novel Imidazolyl Flavonoids As Potent and Selective Protein Tyrosine Phosphatase Inhibitors.

Synthesis and PTP1B/TCPTP Inhibitory Activity Evaluation of Novel 2,5-Disubstituted-1,3,4-thiadiazolamide Derivatives Containing Carbazole/Benzimidazole Moity

Discovery of core-structurally novel PTP1B inhibitors with specific selectivity containing oxindole-fused spirotetrahydrofurochroman by one-pot reaction

Microwave-assisted Construction of Triazole-Linked Amino Acid–glucoside Conjugates As Novel PTP1B Inhibitors

Identification of Lipid-Like Salicylic Acid-Based Derivatives As Potent and Membrane-Permeable PTP1B Inhibitors

Synthesis and Characterization of 5,7-Dihydroxyflavanone Derivatives As Novel Protein Tyrosine Phosphatase 1b Inhibitors

Synthesis of Triazole-Linked Beta-C-glycosyl Dimers As Inhibitors of PTP1B.